ClinicalTrials.gg
RecruitingNCT07527858Updated Oct 20, 2026

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

A Phase 2 interventional study of Denikitug and Nivolumab in Advanced Microsatellite Stable Colorectal Cancer, sponsored by Gilead Sciences. Recruiting at 15 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.
Updated Oct 20, 2026Eligibility revised1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 230 studies testing bevacizumab in Colorectal Neoplasms — 49 open to participants now, 61 under way, 11 of them phase 3. Bevacizumab · Colorectal Neoplasms.

Planned enrollment
56th of 224
170 · median 63
Started
2026
with 12 others
Phase 2
133 of 230
31 open now
Primary completion
2028-12
later than 50 of 60 live
Registered
225th of 230
by date

Among the 230 studies testing bevacizumab in Colorectal Neoplasms, this one is the 56th largest by planned enrollment of the 224 interventional ones that give a count, is one of 13 that started in 2026, is one of 133 in phase 2, reaches primary completion later than 50 of the 60 other live ones, and was the 225th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

49 of the 230 studies testing bevacizumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

43 more — sign in →

By country, each count listing its studies:

All 49 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 230 studies testing bevacizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical study is to learn more about the study drug, Denikitug (DEN, GS-1811), to evaluate the efficacy and safety of Denikitug Monotherapy and Denikitug-based Combinations in participants with advanced microsatellite stable (MSS) colorectal cancer (CRC).

The primary objective of this study is to assess the effect of DEN as monotherapy and in combination with nivolumab (NIVO) or trifluridine-tipiracil (FTD-TPI) and bevacizumab (BVZ) on objective response rate (ORR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1).

03

Conditions studied

  • Advanced Microsatellite Stable Colorectal Cancer
04

Who can participate

The criteria were revised on the registry on Oct 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Medical History/Physical Characteristics

  • or cytologically confirmed unresectable, recurrent, or locally advanced or microsatellite stable colorectal cancer (MSS CRC) (adenocarcinoma, excluding appendix cancer).
  • Documented MSS or proficient mismatch repair (pMMR) disease by local assessment using a validated polymerase chain reaction (PCR) (microsatellite status) and/or immunohistochemistry (IHC) mismatch repair (MMR) assay is required.
  • Has received up to 2 for advanced or metastatic CRC, which must have included at least fluoropyrimidine-, oxaliplatin-, irinotecan-based chemotherapies if indicated; and if applicable: anti-vascular endothelial growth factor (VEGF) therapy, anti epidermal growth factor receptor (EGFR) therapy, encorafenib or adagrasib/sotorasib.
  • Documented progressive disease (PD) by computed tomography (CT) or magnetic resonance imaging (MRI) during or after the most recent therapy per Version 1.1 criteria by investigator assessment.
  • (ECOG) performance status score of 0-1.

Laboratory Assessments

  • Have adequate organ function.

Key Exclusion Criteria with:

Medical Conditions/History:

  • Significant cardiovascular disease.
  • History of disease or active autoimmune disease that has required systemic treatment within 2 years.
  • History of (noninfectious) pneumonitis/interstitial lung disease or current pneumonitis/ interstitial lung disease.
  • History of gastrointestinal (GI) perforation, permanent ileostomy, abdominal abscess or fistula within 6 months, active or uncontrolled GI bleeding within 4 weeks, or any condition associated with significant risk of bleeding or perforation (eg, untreated varices, tumor erosion, recent GI surgery).

Prior/Concurrent Therapy or Clinical Study Experience

Prior treatment with:

  • Trifluridine-tipiracil, regorafenib, or fruquitinib.
  • Any immuno-oncology therapy.
  • Anticancer biologic agent within 4 weeks prior to randomization or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to randomization and have not recovered (ie, Grade 2 or higher is considered not recovered) from AEs from prior anticancer therapy at the time of randomization. Individuals in observational studies are eligible.
  • Allogeneic tissue/solid organ transplantation, including stem cell transplantation. Exception: prior corneal transplant without requirement for systemic agents is allowed.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    DEN monotherapy (Arm A)

    Participants will receive DEN via intravenous (IV) infusion.

    Drug: Denikitug

  • Experimental
    DEN in combination with NIVO (Arm B)

    Participants will receive DEN as an IV infusion in combination with NIVO as an IV infusion.

    Drug: Denikitug · Drug: Nivolumab

  • Experimental
    DEN in combination with Trifluridine-Tipiracil (FTD-TPI) and BVZ (Arm C)

    Participants will receive DEN as an IV infusion in combination with BVZ as an IV infusion and FTD-TPI administered orally. Includes a Safety Run-in cohort (non-randomized cohort) prior to randomization.

    Drug: Denikitug · Drug: Bevacizumab · Drug: Trifluridine-Tipiracil

  • Active comparator
    Standard of care (SOC) alone: BVZ and FTD-TPI (Arm D)

    Participants will receive BVZ as an IV infusion and FTD-TPI administered orally as SOC.

    Drug: Bevacizumab · Drug: Trifluridine-Tipiracil

Interventions

  • Administered Intravenously

    Also known as: GS-1811, DEN

  • Administered Intravenously

    Also known as: NIVO

  • Administered Intravenously

    Also known as: BVZ

  • DrugTrifluridine-Tipiracil

    Administered orally

    Also known as: FTD-TPI

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who have achieved complete response (CR) or partial response (PR) as assessed by the investigator according to RECIST Version 1.1.

    Time frame: Up to 60 months

Secondary outcomes

  1. Duration of response (DOR)

    DOR is defined as the time from first response (CR or PR) as assessed by investigator, per RECIST Version 1.1 until the date of first documented progressive disease (PD) or death, whichever comes first.

    Time frame: Up to 60 months

  2. Progression-Free Survival (PFS)

    PFS is defined as the time from date of randomization until PD or death from any cause, whichever comes first as assessed by the investigator according to RECIST Version 1.1.

    Time frame: Up to 60 months

  3. Overall Survival (OS)

    OS is defined as the length of time from randomization until the date of death from any cause.

    Time frame: Up to 60 months

  4. Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: First dose date up to 120 days post last dose, up to 60 months

  5. Percentage of Participants Experiencing Laboratory Abnormalities According to the NCI CTCAE v5.0

    Time frame: First dose date up to 120 days post last dose, up to 60 months

  6. Pharmacokinetic (PK) Parameter: Serum concentration of Denikitug

    Time frame: Up to 36 months

  7. PK Parameter: Cmax for Denikitug

    Cmax is defined as the maximum observed concentration.

    Time frame: Up to 36 months

  8. PK Parameter: AUCall for Denikitug

    AUCall is defined as the cumulative areas under the curve for all time points.

    Time frame: Up to 36 months

  9. Percentage of Participants who Developed Antidrug Antibody (ADA) Against Denikitug

    Time frame: Up to 36 months

07

Study locations

8 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 31 months is close to that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2026
First posted
Apr 14, 2026
StartActual
May 19, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Royal North Shore Hospital · Saint Leonards, Australia
Oct 20, 2026
Eligibility
1 criterion edited
What changed in the criteria
  • EditedAnticancer biologic agent within 4 weeks prior to randomization or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to randomization and have not recovered (ie, Grade 2 or lesshigher is considered not recovered) from AEs from prior anticancer therapy at the time of randomization. Individuals in observational studies are eligible.
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    1 site added
    Show site
    • Royal North Shore Hospital · Saint Leonards, Australia
    Eligibility 1 criterion edited
    What changed in the criteria
    • EditedAnticancer biologic agent within 4 weeks prior to randomization or have had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to randomization and have not recovered (ie, Grade 2 or lesshigher is considered not recovered) from AEs from prior anticancer therapy at the time of randomization. Individuals in observational studies are eligible.
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07527858
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 14, 2026
Start date
May 19, 2026
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Oct 20, 2026

Study contacts

Gilead Clinical Study Information Center
Contact
GileadClinicalTrials@gilead.com
1-833-445-3230 (GILEAD-0)
Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Denikitug · Bevacizumab

Start the discussion